Impact of Cardiac Rehabilitation Programs on Left Ventricular Remodeling After Acute Myocardial Infarction - the REHAB Trial

While the role of early mobilization in the immediate postinfarction period has been well demonstrated, little is known in present about the link between early mobilization and reduction of systemic inflammation. At the same time, the impact of early mobilization on regression of left ventricular remodeling has not been elucidated so far.

The study will be a single-center, observational, non-randomized study, which will be carried out in the Center of Advanced Research in Multimodal Cardiac Imaging Cardiomed, including 100 patients with AMI, presenting with either ST-segment elevation acute myocardial infarction (STEMI) or non-ST-segment elevation AMI (NSTEMI). According to the moment of mobilization after AMI patients will be distributed in two groups: group 1 - patients with early mobilization (<2 days after the onset of symptoms), and group 2 - subjects with delayed mobilization after AMI (>2 days after the onset of symptoms).

Each patient will be evaluated in terms of systemic inflammatory status in the immediate postinfarction phase, at baseline and at 7 days after AMI. In order to assess ventricular function and remodeling, extent of myocardial scar and transmurality index, late gadolinium enhancement CMR will be performed for each patient.

The study will be conducted over a period of 2 years, in which patients will be examined at baseline, and will be followed-up for 1 year for occurrence of MACE.

All patients will sign an informed written consent prior to study enrollment.

Study objectives:

Primary: to evaluate the impact of early mobilization after AMI on the ventricular remodeling in the post-infarction period, as assessed by CMR imaging. Secondary: to assess the rate of in-hospital mortality and the rate of repeated revascularization or MACE (including cardiovascular death or stroke) in patients with early mobilization as compared to those with delayed mobilization, and the effect of early mobilization on systemic inflammation in the immediate postinfarction phase.

Study Timeline:

• Baseline (day 0):
• Achieve written informed consent form all patients
• Check all inclusion/exclusion criteria
• Record demographic information, medical records, cardiovascular risk factors
• Perform and record physical examination and 12-lead ECG
• Laboratory analysis (CBC, routine biochemistry, inflammatory biomarkers, acute adhesion molecules)
• Transthoracic echocardiography / speckle tracking
• Visit 1 (day 7 / discharge from the hospital):
• hs-CRP assessment
• Visit 2 (month 1):
• LGE-CMR (myocardial fibrosis/scar, infarct size, transmurality, remodeling)
• Visit 3,4,5 (month 3,6,9):
• Record results of physical exam, medical records, ECG
• Transthoracic echocardiography / speckle tracking
• Final study visit (month 12):
• Record results of physical exam, medical records, ECG
• Transthoracic echocardiography / speckle tracking
• End-point assessment

Study procedures:

• Medical records, physical exam;
• Laboratory analysis (complete blood count, biochemistry, serum levels of hs-CRP, MMPs, IL6, NT-pro-BNP);
• Electrocardiography
• Transthoracic echocardiography for assessment of left ventricular systolic and diastolic performance, speckle tracking echocardiography, Dobutamine viability test
• Late gadolinium enhancement CMR for evaluation of ventricular function and remodeling, extent of myocardial scar and transmurality index.

Inclusion criteria

• Patients with AMI in the last 12 hours;
• Successful revascularization of the culprit artery within the first 12 hours after the onset of symptoms in STEMI or within first 48 hours in NSTEMI (according to the risk class);
• Signed written informed consent.

Exclusion criteria

• Patient refusal;
• Any condition that would contraindicate CMR examination;
• Women during pregnancy or lactation period;
• Women able to procreate without any contraceptive usage;
• Chronic kidney disease (glomerular filtration rate <60ml/min/1.73m2) or acute renal injury that requires hemodialysis;
• Any type of neoplasia documented in the last 3 years before randomization;
• Expectation of life < 1 year.